What is HC Wainwright’s Forecast for APLS Q1 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Apellis Pharmaceuticals in a research note issued on Thursday, May 8th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.29) for the quarter. HC Wainwright currently has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.03) EPS, FY2028 earnings at $2.17 EPS and FY2029 earnings at $3.68 EPS.

Several other research analysts have also recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday. Bank of America cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $41.00 to $23.00 in a research report on Friday. JPMorgan Chase & Co. increased their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $30.00 to $26.00 and set an “equal weight” rating on the stock in a report on Thursday. Finally, Scotiabank dropped their price objective on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating for the company in a report on Thursday. Nine research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.37.

Apellis Pharmaceuticals Price Performance

APLS opened at $17.30 on Friday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock’s 50 day simple moving average is $21.31 and its 200 day simple moving average is $27.12. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -8.52 and a beta of 0.73. Apellis Pharmaceuticals has a 1 year low of $16.65 and a 1 year high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The business had revenue of $149.90 million for the quarter, compared to analysts’ expectations of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.54) earnings per share.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,569 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 6,115 shares of company stock valued at $154,684. Insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of APLS. GF Fund Management CO. LTD. boosted its position in Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after purchasing an additional 573 shares during the last quarter. Xponance Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 5.6% in the fourth quarter. Xponance Inc. now owns 14,072 shares of the company’s stock worth $449,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after buying an additional 758 shares during the period. Woodline Partners LP increased its holdings in Apellis Pharmaceuticals by 0.5% during the fourth quarter. Woodline Partners LP now owns 189,477 shares of the company’s stock valued at $6,046,000 after buying an additional 913 shares during the last quarter. Finally, Signaturefd LLC raised its position in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).